首页> 外文OA文献 >Deficiency of sphingosine-1-phosphate receptor 3 does not affect the skeletal phenotype of mice lacking sphingosine-1-phosphate lyase
【2h】

Deficiency of sphingosine-1-phosphate receptor 3 does not affect the skeletal phenotype of mice lacking sphingosine-1-phosphate lyase

机译:鞘氨酸-1-磷酸盐受体3的缺乏不会影响缺乏鞘氨醇-1-磷酸裂解酶的小鼠的骨骼表型

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Albeit osteoporosis is one of the most prevalent disorders in the aged population, treatment options stimulating the activity of bone-forming osteoblasts are still limited. We and others have previously identified sphingosine-1-phosphate (S1P) as a bone remodeling coupling factor, which is released by bone-resorbing osteoclasts to stimulate bone formation. Moreover, S1pr3, encoding one of the five known S1P receptors (S1P3), was found differentially expressed in osteoblasts, and S1P3 deficiency corrected the moderate high bone mass phenotype of a mouse model (deficient for the calcitonin receptor) with increased S1P release from osteoclasts. In the present study we addressed the question, if S1P3 deficiency would also influence the skeletal phenotype of mice lacking S1P-lyase (encoded by Sgpl1), which display markedly increased S1P levels due to insufficient degradation. Consistent with previous reports, the majority of Sgpl1-deficient mice died before or shortly after weaning, and this lethality was not influenced by additional S1P3 deficiency. At 3 weeks of age, Sgpl1-deficient mice displayed increased trabecular bone mass, which was associated with enhanced osteoclastogenesis and bone resorption, but also with increased bone formation. Most importantly however, none of the skeletal parameters assessed by μCT, histomorphometry and serum analyses were significantly influenced by additional S1P3 deficiency. Taken together, our findings fully support the concept that S1P is a potent osteoanabolic molecule, although S1P3 is not the sole receptor mediating this influence. Since S1P receptors are considered excellent drug targets, it is now required to screen for the impact of other family members on bone formation.
机译:虽然骨质疏松症是在老年人口最普遍的疾病之一,刺激骨形成的成骨细胞的活性的治疗选择仍然是有限的。我们和其他人先前确定的鞘氨醇-1-磷酸(S1P),为骨重塑耦合因子,其通过骨再吸收的破骨细胞释放,以刺激骨形成。此外,S1pr3,编码5个已知S1P受体(S1P3)中的一个,被发现差异在成骨细胞中表达,和S1P3不足校正的小鼠模型(缺陷的降钙素受体)的适度高骨量表现型与破骨细胞S1P释放增加。在本研究中,我们处理的问题,如果S1P3不足也会影响小鼠的骨骼肌表型缺乏S1P裂解酶(由Sgpl1编码),其显示显着增加S1P水平由​​于降解不足。与以前的报道一致,多数Sgpl1缺陷小鼠断奶之前或之后不久死亡,而这种杀伤力是没有额外的S1P3缺乏的影响。在3周龄,Sgpl1缺陷型小鼠显示具有骨形成的增加而增加小梁骨量,将其与破骨细胞形成增强和骨吸收有关,但也。最重要但是,没有通过μCT评估骨骼参数,组织形态测定和血清分析是显著的额外S1P3缺乏的影响。总之,我们的研究结果完全支持的概念,即S1P是一种有效的骨代谢的分子,虽然S1P3不是唯一的受体介导这种影响。由于S1P受体被认为是优秀的药物靶点,现在需要屏幕的其他家庭成员对骨形成的影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号